Skip to main content
. 2000 Aug;44(8):2109–2117. doi: 10.1128/aac.44.8.2109-2117.2000

TABLE 2.

Characteristics and antiretroviral treatment for patients whose isolates displayed the Q151M or T69S-SS mutationa

Mutation Patient Sex Origin Transmission route Yr of first HIV detection Date (mo/yr) of Q151M or T69S-SS detection Viral load (log10 no. of RNA copies/ml CD4 count (no. of cells/μl)b Treatment duration (mo)c Antiretroviral treatmentd
Q151M IT2 M I Homosexual 1992 2/1993 ND 207 2 ZDV-ddC
Q151M IT1 M I IVDU 1988 10/1993 5.5 360 42 ZDV/ZDV-ddI
Q151Q/M SP1 M E Homosexual 1990 3/1996 5.3 50 8 ZDV-ddC/ZDV-ddC-IDV
Q151M SP2 M E IVDU 1986 2/1995 2.3 640 17 ZDV/ZDV-d4T
Q151M SW1 M S Homosexual 1983 3/1995 5 430 7 ZDV/ZDV-ddI/ZDV-d4T-IDV/3TC-d4T-RTV-SQV
Q151M SW2 M S Homosexual 1987 10/1995 4.2 6 34 ZDV/ZDV-ddI/ddI/ZDV-ddI/ddI/ddI-3TC/ddI-3TC-IDV/ZDV-d4T-3TC-IDV/ZDV-d4T-3TC-SQV-RTV/d4T-3TC-SQV-RTV
T69S-SS SW3 M S Homosexual 1989 8/1995 5.1 60 20 ZDV/ZDV/ZDV-ddI/−/ZDV-ddI/ZDV-ddI-3TC/ZDV-ddI-3TC-IDV
T69S-SS CHG F Z Heterosexual 1990 4/1995 3.8 293 51 ZDV/ddI/−/ZDV-ddC/ZDV-3TC/d4T-3TC
a

Abbreviations: M, male; F, female; I, Italy; E, Spain; S, Sweden; Z, Switzerland; IVDU, intravenous drug user; ND, not determined; ZDV, zidovudine; ddI, didanosine; ddC, zalcitabine; d4T, stavudine; 3TC, lamivudine; SQV, saquinavir; IDV, indinavir; RTV, ritonavir. 

b

At the time that the Q151M or T69S-SS mutation was first identified; for viral load first available value is given. 

c

Total duration of treatment with nucleoside analogues before Q151M or T69S-SS was identified retrospectively. 

d

Slashes denote successive treatments, minus signs indicate no treatment, and hypens mark combination treatments. The presence of Q151M or T69S-SS is noted by underscores; the treatments that the patients were receiving at the time the original samples (that were included in the screening) were obtained are in boldface type.